BioCentury
ARTICLE | Targets & Mechanisms

Raising metabolism

Why immuno-metabolism is the next white space area of cancer immunotherapy

April 26, 2018 11:54 PM UTC

In the wake of the failure of ECHO-301, drug developers are asking whether the trial design or the target is at fault. But while the value of IDO1 as a target is still in doubt, the result has done little to dampen enthusiasm among immuno-oncologists for the idea of interrupting metabolic pathways to treat cancer.

Cancer metabolism has long been a focus in oncology, but innovators have recently turned to new ways of blocking metabolic processes related to immunosuppression in the tumor microenvironment...